View highlights and coverage from leading international Neurology congresses
We had the pleasure of meeting up with Dr Johanna Ospel (University Hospital, Basel, Switzerland) to discuss the findings from the ESCAPE-NA1 Trial. The abstract entitled “Predictors and Clinical Impact of Infarct Progression Rate in the ESCAPE-NA1 Trial” was presented at the 7th European Stroke Conference, 1-3 September 2021. Questions: Why is it so important […]
touchNEUROLOGY joins Prof James Galvin (University of Miami Miller School of Medicine, Miami, FL, USA) to discuss aducanumab for the treatment of Alzheimer’s disease, and what this recent accelerated approval might mean for future potential treatments. Questions 1. Why has the recent FDA accelerated approval of aducanumab for Alzheimer’s disease been so controversial? (00:13-02:00) 2. […]
We had the pleasure of meeting with Robert Music (Chief Executive of The Migraine Trust), to discuss a new report entitled: ‘State of the Migraine Nation, Dismissed for too long’, put together by The Migraine Trust. The report addresses the issues in the diagnosis, treatment and access to specialist care, and recommendations for improving migraine […]
It was a pleasure to meet with Prof. Xavier Montalban (Multiple Sclerosis Centre of Catalonia, Vall d’Hebron, Barcelona Hospital Campus, Spain) to discuss the use of ofatumumab as a treatment option for relapsing multiple sclerosis. The abstract entitled: ‘Effectiveness and Tolerability of Ofatumumab Versus First-line DMTs in Early RMS Patients: Phase 3b STHENOS Study Design’ […]
It was a pleasure to meet with Prof. Xavier Montalban (Multiple Sclerosis Centre of Catalonia, Vall d’Hebron, Barcelona Hospital Campus, Spain) to discuss the phase 3b STHENOS study, investigating the use of ofatumumab as a treatment option for relapsing multiple sclerosis. The abstract entitled: ‘Effectiveness and Tolerability of Ofatumumab Versus First-line DMTs in Early RMS […]
We had the pleasure of meeting up with Prof. Michael Hill (University of Calgary, Calgary, Canada) to discuss the use of nerinetide in the treatment of patients who had an acute ischaemic stroke, and the findings from the ESCAPE-NA1 trial. The session entitled “Nerinetide for LVO Neuroprotection: Fact or Fiction?” was presented at the 7th […]
touchNEUROLOGY joins Gabriel de Erausquin (UT Health San Antonio, TX, USA) at AAIC 2021 to discuss the Alzheimer’s Association-led Global SARS-CoV-2 Consortium and the links between long-term cognitive dysfunction, acceleration of Alzheimer’s symptoms and COVID-19. Questions Could you tell us a little about the Alzheimer’s Association-led global SARS-CoV-2 consortium? (00:30-02:07) What were the aims and […]
touchNEUROLOGY joins Jeffrey Cummings (University of Nevada, Las Vegas, NV, USA) at AAIC 2021 to discuss the EMERGE clinical trial findings and what this means for the use of aducanumab on the treatment of patients with Alzheimer’s disease. The abstract entitled “Item-level analysis of clinical measures in patients with early symptomatic Alzheimer’s disease following treatment […]
touchNEUROLOGY joins Prof Munro Cullum (UT Southwestern Medical Center, Dallas, TX, USA) at AAIC 2021 to discuss the challenges faced during the COVID-19 pandemic and the impact of telehealth on clinical practice. Questions 1. What challenges to dementia research have been posed by the COVID-19 pandemic and how have telehealth procedures helped to overcome these? […]
Get the latest clinical insights from touchNEUROLOGY
